Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $48.67

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $48.67.

A number of brokerages have recently issued reports on KYMR. Oppenheimer reissued an “outperform” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday, July 10th. Morgan Stanley upped their price target on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 14th. B. Riley lifted their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Leerink Partners reiterated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $49.79 on Friday. The stock has a 50-day moving average of $45.28 and a 200 day moving average of $39.07. Kymera Therapeutics has a one year low of $9.60 and a one year high of $50.69. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of -19.84 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $12.55 million. During the same period in the prior year, the firm earned ($0.67) EPS. The company’s revenue was up 55.2% compared to the same quarter last year. On average, equities analysts predict that Kymera Therapeutics will post -2.87 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the transaction, the director now owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 495,605 shares of company stock worth $19,303,364. 15.82% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Kymera Therapeutics by 1.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock valued at $7,808,000 after acquiring an additional 4,951 shares in the last quarter. Norges Bank purchased a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $12,834,000. UBS Group AG lifted its position in shares of Kymera Therapeutics by 84.6% in the 4th quarter. UBS Group AG now owns 300,463 shares of the company’s stock worth $7,650,000 after purchasing an additional 137,704 shares during the period. Trexquant Investment LP bought a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $5,183,000. Finally, Quest Partners LLC purchased a new position in Kymera Therapeutics during the fourth quarter valued at approximately $78,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.